Alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as RNA interference, or RNAi. With RNAi technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today’s medicines.

Recent Milestones
edit

Alnylam Pharmaceuticals — Alnylam reaps $29M harvest in new ag bio deal with Monsanto (8/28/12)

Posted 8/28/12 at 7:42pm via fiercebiotech.com
Alnylam Pharmaceuticals — Alnylam gets $3.2M payment from Glaxo (7/30/12)

Posted 7/30/12 at 6:31pm via masshightech.com
Alnylam Pharmaceuticals — promoted Akshay K. Vaishnaw, M.D., Ph.D., to the new position of chief medical officer (6/13/11)

Posted 6/14/11 at 5:53am via masshightech.com
Alnylam Pharmaceuticals received $10M in Venture Round funding. (3/28/11)

Posted 3/28/11 at 6:51pm via masshightech.com
Went public with stock symbol NASDAQ:ALNY.

Posted 3/28/11 at 6:55pm
Alnylam Pharmaceuticals added John Maraganore as CEO.

Posted 3/28/11 at 6:51pm
Alnylam Pharmaceuticals added Barry Greene as President and COO.

Posted 3/28/11 at 6:51pm